Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) modeling and simulations, which were used to inform the pha...

Full description

Bibliographic Details
Main Authors: Chi‐Chung Li, Tiffini Voss, Ken Kowalski, Bei Yang, Huub Jan Kleijn, Christopher J. Jones, Rolien Bosch, David Michelson, Matthew DeAngelis, Yang Xu, Iris Xie, Prajakti A. Kothare
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12730

Internet

https://doi.org/10.1111/cts.12730

Similar Items